Among NSCLC subtypes, adenocarcinoma is more prone to BM, and the prognosis and treatment strategy for lung adenocarcinoma patients are different from those of patients with other lung cancer types, especially for patients with EGFR gene mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.